Does the media refer more to INNV or BLLN?

In the previous week, Billiontoone had 3 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Billiontoone and 1 mentions for InnovAge. Billiontoone's average media sentiment score of 0.04 beat InnovAge's score of 0.00 indicating that Billiontoone is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Billiontoone 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CELC or INNV?

InnovAge has higher revenue and earnings than Celcuity. InnovAge is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$3.90 N/A InnovAge $853.70M 1.91 -$30.31M -$0.09 N/A

Is CELC or INNV more profitable?

Celcuity has a net margin of 0.00% compared to InnovAge's net margin of -1.22%. InnovAge's return on equity of -4.73% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -244.61% -50.22% InnovAge -1.22% -4.73% -2.20%

Which has preferable valuation & earnings, SHC or INNV?

Sotera Health has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.39 $77.94M $0.41 43.73 InnovAge $853.70M 1.91 -$30.31M -$0.09 N/A

Does the media favor SHC or INNV?

In the previous week, Sotera Health and Sotera Health both had 1 articles in the media. Sotera Health's average media sentiment score of 0.95 beat InnovAge's score of 0.00 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer INNV or CAI?

In the previous week, Caris Life Sciences had 3 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Caris Life Sciences and 1 mentions for InnovAge. Caris Life Sciences' average media sentiment score of 0.50 beat InnovAge's score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InnovAge 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, INNV or RDNT?

RadNet has higher revenue and earnings than InnovAge. RadNet is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InnovAge $853.70M 1.91 -$30.31M -$0.09 N/A RadNet $2.04B 2.65 -$18.65M -$0.18 N/A

Is INNV or RDNT more profitable?

RadNet has a net margin of -0.66% compared to InnovAge's net margin of -1.22%. RadNet's return on equity of 2.77% beat InnovAge's return on equity. Company Net Margins Return on Equity Return on Assets InnovAge -1.22% -4.73% -2.20% RadNet -0.66% 2.77% 0.97%

InnovAge (INNV) Competitors

$11.99 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$12.00 +0.00 (+0.04%)

As of 07/2/2026 06:29 PM Eastern

Compare

INNV vs. BLLN, CELC, SHC, CAI, and RDNT

Should you buy InnovAge stock or one of its competitors? MarketBeat compares InnovAge with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InnovAge include Billiontoone (BLLN), Celcuity (CELC), Sotera Health (SHC), Caris Life Sciences (CAI), and RadNet (RDNT). These companies are all part of the "healthcare" industry.

How does InnovAge compare to Billiontoone?

InnovAge (NASDAQ:INNV) and Billiontoone (NASDAQ:BLLN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Billiontoone has lower revenue, but higher earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.91	-$30.31M	-$0.09	N/A
Billiontoone	$354.54M	15.61	$7.45M	$0.55	218.82

In the previous week, Billiontoone had 3 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Billiontoone and 1 mentions for InnovAge. Billiontoone's average media sentiment score of 0.04 beat InnovAge's score of 0.00 indicating that Billiontoone is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Billiontoone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

InnovAge presently has a consensus price target of $7.00, indicating a potential downside of 41.62%. Billiontoone has a consensus price target of $126.00, indicating a potential upside of 4.69%. Given Billiontoone's stronger consensus rating and higher probable upside, analysts clearly believe Billiontoone is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

12.3% of InnovAge shares are owned by institutional investors. 1.0% of InnovAge shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Billiontoone has a net margin of 0.00% compared to InnovAge's net margin of -1.22%. Billiontoone's return on equity of 0.00% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Billiontoone	N/A	N/A	N/A

Summary

Billiontoone beats InnovAge on 12 of the 15 factors compared between the two stocks.

How does InnovAge compare to Celcuity?

Celcuity (NASDAQ:CELC) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Celcuity currently has a consensus price target of $152.09, indicating a potential upside of 40.89%. InnovAge has a consensus price target of $7.00, indicating a potential downside of 41.62%. Given Celcuity's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Celcuity has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market. Comparatively, InnovAge has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

InnovAge has higher revenue and earnings than Celcuity. InnovAge is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A
InnovAge	$853.70M	1.91	-$30.31M	-$0.09	N/A

Celcuity has a net margin of 0.00% compared to InnovAge's net margin of -1.22%. InnovAge's return on equity of -4.73% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
InnovAge	-1.22%	-4.73%	-2.20%

In the previous week, InnovAge had 1 more articles in the media than Celcuity. MarketBeat recorded 1 mentions for InnovAge and 0 mentions for Celcuity. Celcuity's average media sentiment score of 0.00 equaled InnovAge'saverage media sentiment score.

Company	Overall Sentiment
Celcuity	Neutral
InnovAge	Neutral

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 12.3% of InnovAge shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 1.0% of InnovAge shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Celcuity and InnovAge tied by winning 7 of the 14 factors compared between the two stocks.

How does InnovAge compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and InnovAge (NASDAQ:INNV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 12.3% of InnovAge shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 1.0% of InnovAge shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sotera Health currently has a consensus price target of $20.25, indicating a potential upside of 12.94%. InnovAge has a consensus price target of $7.00, indicating a potential downside of 41.62%. Given Sotera Health's stronger consensus rating and higher possible upside, research analysts clearly believe Sotera Health is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

Sotera Health has higher revenue and earnings than InnovAge. InnovAge is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.39	$77.94M	$0.41	43.73
InnovAge	$853.70M	1.91	-$30.31M	-$0.09	N/A

In the previous week, Sotera Health and Sotera Health both had 1 articles in the media. Sotera Health's average media sentiment score of 0.95 beat InnovAge's score of 0.00 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sotera Health has a net margin of 9.91% compared to InnovAge's net margin of -1.22%. Sotera Health's return on equity of 39.73% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
InnovAge	-1.22%	-4.73%	-2.20%

Sotera Health has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market. Comparatively, InnovAge has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Summary

Sotera Health beats InnovAge on 15 of the 15 factors compared between the two stocks.

How does InnovAge compare to Caris Life Sciences?

InnovAge (NASDAQ:INNV) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Caris Life Sciences had 3 more articles in the media than InnovAge. MarketBeat recorded 4 mentions for Caris Life Sciences and 1 mentions for InnovAge. Caris Life Sciences' average media sentiment score of 0.50 beat InnovAge's score of 0.00 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InnovAge	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InnovAge has higher revenue and earnings than Caris Life Sciences. InnovAge is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.91	-$30.31M	-$0.09	N/A
Caris Life Sciences	$348.89M	14.83	-$68.09M	-$7.61	N/A

InnovAge currently has a consensus target price of $7.00, indicating a potential downside of 41.62%. Caris Life Sciences has a consensus target price of $27.56, indicating a potential upside of 50.58%. Given Caris Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Caris Life Sciences has a net margin of 3.75% compared to InnovAge's net margin of -1.22%. Caris Life Sciences' return on equity of 98.28% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
Caris Life Sciences	3.75%	98.28%	48.87%

12.3% of InnovAge shares are owned by institutional investors. 1.0% of InnovAge shares are owned by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Caris Life Sciences beats InnovAge on 11 of the 15 factors compared between the two stocks.

How does InnovAge compare to RadNet?

InnovAge (NASDAQ:INNV) and RadNet (NASDAQ:RDNT) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

12.3% of InnovAge shares are owned by institutional investors. Comparatively, 77.9% of RadNet shares are owned by institutional investors. 1.0% of InnovAge shares are owned by insiders. Comparatively, 5.6% of RadNet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InnovAge presently has a consensus price target of $7.00, indicating a potential downside of 41.62%. RadNet has a consensus price target of $87.43, indicating a potential upside of 27.17%. Given RadNet's stronger consensus rating and higher probable upside, analysts clearly believe RadNet is more favorable than InnovAge.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InnovAge	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

RadNet has a net margin of -0.66% compared to InnovAge's net margin of -1.22%. RadNet's return on equity of 2.77% beat InnovAge's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InnovAge	-1.22%	-4.73%	-2.20%
RadNet	-0.66%	2.77%	0.97%

RadNet has higher revenue and earnings than InnovAge. RadNet is trading at a lower price-to-earnings ratio than InnovAge, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InnovAge	$853.70M	1.91	-$30.31M	-$0.09	N/A
RadNet	$2.04B	2.65	-$18.65M	-$0.18	N/A

InnovAge has a beta of 0.36, suggesting that its stock price is 64% less volatile than the broader market. Comparatively, RadNet has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

In the previous week, InnovAge had 1 more articles in the media than RadNet. MarketBeat recorded 1 mentions for InnovAge and 0 mentions for RadNet. RadNet's average media sentiment score of 1.00 beat InnovAge's score of 0.00 indicating that RadNet is being referred to more favorably in the news media.

Company	Overall Sentiment
InnovAge	Neutral
RadNet	Positive

Summary

RadNet beats InnovAge on 14 of the 17 factors compared between the two stocks.

Get InnovAge News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INNV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INNV vs. The Competition

Export

Metric	InnovAge	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.63B	$9.63B	$7.16B	$12.48B
Dividend Yield	N/A	1.62%	2.66%	6.52%
P/E Ratio	-133.22	27.84	28.02	24.70
Price / Sales	1.91	18.50	540.37	99.46
Price / Cash	N/A	114.69	49.26	57.09
Price / Book	6.81	6.19	10.96	6.46
Net Income	-$30.31M	$179.69M	$3.57B	$337.01M
7 Day Performance	11.12%	3.82%	2.12%	1.69%
1 Month Performance	64.25%	10.36%	5.25%	3.81%
1 Year Performance	170.65%	14.53%	33.29%	23.90%

InnovAge Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INNV InnovAge	1.5081 of 5 stars	$11.99 flat	$7.00 -41.6%	+170.7%	$1.63B	$853.70M	N/A	2,440	News Coverage
BLLN Billiontoone	2.5745 of 5 stars	$119.55 -0.7%	$126.00 +5.4%	N/A	$5.50B	$305.11M	217.35	620	News Coverage Insider Trade Gap Up
CELC Celcuity	2.8139 of 5 stars	$104.62 +2.0%	$152.09 +45.4%	+682.8%	$5.10B	N/A	N/A	40
SHC Sotera Health	3.3121 of 5 stars	$17.75 +1.3%	$20.25 +14.1%	+52.7%	$5.06B	$1.19B	43.29	3,000
CAI Caris Life Sciences	4.0913 of 5 stars	$17.85 -2.6%	$27.56 +54.4%	N/A	$5.04B	$812.03M	N/A	1,846	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INNV) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InnovAge (INNV) Competitors

INNV vs. BLLN, CELC, SHC, CAI, and RDNT

How does InnovAge compare to Billiontoone?

Summary

How does InnovAge compare to Celcuity?

Summary

How does InnovAge compare to Sotera Health?

Summary

How does InnovAge compare to Caris Life Sciences?

Summary

How does InnovAge compare to RadNet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InnovAge (INNV) Competitors

INNV vs. BLLN, CELC, SHC, CAI, and RDNT

How does InnovAge compare to Billiontoone?

Which has stronger earnings and valuation, INNV or BLLN?

Does the media refer more to INNV or BLLN?

Do analysts rate INNV or BLLN?

Do institutionals and insiders have more ownership in INNV or BLLN?

Is INNV or BLLN more profitable?

Summary

How does InnovAge compare to Celcuity?

Do analysts recommend CELC or INNV?

Which has more volatility and risk, CELC or INNV?

Which has preferable valuation & earnings, CELC or INNV?

Is CELC or INNV more profitable?

Does the media refer more to CELC or INNV?

Do insiders and institutionals have more ownership in CELC or INNV?

Summary

How does InnovAge compare to Sotera Health?

Do insiders & institutionals have more ownership in SHC or INNV?

Do analysts recommend SHC or INNV?

Which has preferable valuation & earnings, SHC or INNV?

Does the media favor SHC or INNV?

Is SHC or INNV more profitable?

Which has more volatility & risk, SHC or INNV?

Summary

How does InnovAge compare to Caris Life Sciences?

Does the media prefer INNV or CAI?

Which has preferable earnings & valuation, INNV or CAI?

Do analysts rate INNV or CAI?

Is INNV or CAI more profitable?

Do insiders and institutionals believe in INNV or CAI?

Summary

How does InnovAge compare to RadNet?

Do institutionals & insiders believe in INNV or RDNT?

Do analysts prefer INNV or RDNT?

Is INNV or RDNT more profitable?

Which has preferable valuation and earnings, INNV or RDNT?

Which has more risk & volatility, INNV or RDNT?

Does the media prefer INNV or RDNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INNV vs. The Competition

InnovAge Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools